Related Experiment Video
Updated: May 5, 2026
08:39
Assessing Cortical Cerebral Microinfarcts on High Resolution MR Images
Published on: November 20, 2015
14.0K
Association Between Cognitive Impairment and Multimodal MRI Markers in Patients with Cerebral Microbleeds: A
Peiqing Zhuang1, Jiyang Liu2, Xuehua Cai2
1Department of Medical Imaging, Quanzhou First Hospital, Quanzhou First Hospital, Quanzhou, Fujian, 362000, People's Republic of China.
International Journal of General Medicine
|February 25, 2026
Summary
Cognitive impairment in cerebral microbleed (CMB) patients is linked to imaging markers like lesion burden and white matter changes. These multimodal MRI findings may help predict and monitor cognitive dysfunction.
Area of Science:
- Neurology
- Radiology
- Neuroimaging
Background:
- Cerebral microbleeds (CMBs) are associated with cognitive impairment.
- Multimodal magnetic resonance imaging (MRI) offers potential markers for understanding CMB-related cognitive dysfunction.
Purpose of the Study:
- To investigate the association between cognitive impairment and multimodal MRI markers in patients with CMBs.
- To identify imaging predictors of cognitive dysfunction in CMB patients.
Main Methods:
- A case-control study involving 71 CMB patients and 65 healthy controls.
- Cognitive function assessed using the Montreal Cognitive Assessment (MoCA).
- Multimodal MRI including SWI for CMBs and DTI for FA and ADC values; statistical analyses included Spearman correlation and multivariate regression.
Main Results:
- CMB patients showed lower MoCA scores and higher CMB burden compared to controls.
- Reduced FA and increased ADC in specific brain regions were observed in CMB patients.
- CMB burden, reduced FA, increased ADC, and basal ganglia involvement were identified as independent risk factors for cognitive impairment.
Conclusions:
- Cognitive impairment in CMB patients is associated with lesion burden and white matter alterations detected by multimodal MRI.
- These imaging markers may aid in early risk stratification and targeted monitoring of cognitive decline in CMB patients.
